Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8246)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 26, 2022 (publication date) through Apr 7, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol 2022; 14(6): 329-342 [PMID: 35979179 DOI: 10.4330/wjc.v14.i6.329] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v14/i6/329.htm |
| Number | Citing Articles |
| 1 |
Li-Nong JI, Yun-Dai CHEN. Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes. Journal of Geriatric Cardiology 2024; 21(7): 689 doi: 10.26599/1671-5411.2024.07.007
|
| 2 |
Vinod Kumar , V B Amulya , Manjari Sharma , B V Saikrupa . Combination Therapy of SGLT 2 Inhibitors and GLP 1 Receptor Agonists for Glycaemic Management through Weight Reduction. Journal of Drug Delivery and Therapeutics 2025; 15(1): 142 doi: 10.22270/jddt.v15i1.6914
|
| 3 |
Antonina Kedyk, Oleksandr Kutsyn. Metabolic effects of empagliflozine. Diabetes Obesity Metabolic Syndrome 2022; (5): 38 doi: 10.57105/2415-7252-2022-5-04
|
| 4 |
Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiromichi Wakui, Hiroshi Takeda, Hisashi Yokomizo, Kei Takeshita, Keiichi Chin, Keizo Kanasaki, Masaaki Miyauchi, Masuo Saburi, Miwa Morita, Miwako Yomota, Moritsugu Kimura, Nobuo Hatori, Shinichi Nakajima, Shun Ito, Takashi Murata, Takaya Matsushita, Takayuki Furuki, Takuya Hashimoto, Tomoya Umezono, Yoshimi Muta, Yuichi Takashi, Kouichi Tamura. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism 2024; 26(8): 3248 doi: 10.1111/dom.15652
|
| 5 |
Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study. Asian Journal of Medical Sciences 2024; 15(7): 137 doi: 10.71152/ajms.v15i7.3404
|
| 6 |
André J. Scheen. GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy. Drugs 2024; 84(11): 1347 doi: 10.1007/s40265-024-02090-9
|
| 7 |
Lixin Du, Jiao Qin, Dengchuan Wang, Yunhui Zhao, Ning Xu, Chaowen Wu, Jianpeng Yuan. Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1028486
|
| 8 |
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, Vasileios Anastasiou, Stylianos Daios, Spyridon-Filippos Papadopoulos, Matthaios Didagelos, John Parissis, Theodoros Karamitsos, Kalliopi Kotsa, Antonios Ziakas, Vasileios Kamperidis. Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review. Medicina 2024; 60(6): 912 doi: 10.3390/medicina60060912
|
| 9 |
Aftab Ahmad, Hani Sabbour. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02192-4
|
| 10 |
Sanket Seksaria, Bhaskar Jyoti Dutta, Mandeep Kaur, Ghanshyam Das Gupta, Surendra H. Bodakhe, Amrita Singh. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder:
Recent Updates of Clinical and Pre-clinical Evidence. Current Diabetes Reviews 2024; 20(6) doi: 10.2174/1573399820666230809152148
|
| 11 |
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. eClinicalMedicine 2023; 64: 102181 doi: 10.1016/j.eclinm.2023.102181
|